Adaptive Biotechnologies Corporation (ADPT)Healthcare | Diagnostics & Research | Seattle, United States | NasdaqGS
26.44 USD
+0.28
(1.070%)
⇧
(Aug. 27, 2026, 4 p.m.
EDT)
After hours: 26.80 +0.36 (1.362%) ⇧ (Aug. 27, 2026, 7:41 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 2:25 a.m. EDT
The long-term investment case is severely compromised by a brutal six-year price trajectory that erased over 70% of shareholder value, driven by five consecutive years of negative annual returns. Despite a massive 195% rebound in the most recent year, the underlying business remains unprofitable with negative operating margins and a forward P/E that is mathematically undefined due to losses. The balance sheet is fragile, carrying debt nearly equal to its cash reserves while generating negative operating cash flow. While the stock recently rallied on a business split announcement, the fundamental reality of a loss-making biotech firm with no dividend history makes it a speculative gamble rather than an investment. The short-term outlook is neutral at best; the statistical forecast offers only a weak lean upward, which is insufficient to overcome the structural risks of the business model and the lingering threat of further downside given the high beta and insider selling activity. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.241733 |
| AutoARIMA | 0.254459 |
| AutoETS | 0.278209 |
| MSTL | 0.285105 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 9.17 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.113 |
| Excess Kurtosis | -0.99 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 272.464 |
| Revenue per Share | 1.984 |
| Market Cap | 4,219,714,048 |
| Forward P/E | -143.13 |
| Beta | 2.09 |
| Profit Margins | -20.73% |
| Website | https://www.adaptivebiotech.com |
As of Aug. 22, 2026, 2:25 a.m. EDT: Speculators are positioning defensively with heavy out-of-the-money put volume relative to calls, creating a 'bear put' skew where protection is priced significantly higher than upside speculation. Open interest is concentrated deep in-the-money at strikes like $15 and $22.50, suggesting a floor expectation rather than a breakout thesis. The lack of significant call open interest above current prices indicates a lack of aggressive bullish positioning.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.0060699 |
| Address1 | 1,165 Eastlake Avenue East |
| All Time High | 71.25 |
| All Time Low | 2.28 |
| Ask | 26.65 |
| Ask Size | 1 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 1,846,560 |
| Average Daily Volume3 Month | 2,954,612 |
| Average Volume | 2,954,612 |
| Average Volume10Days | 1,846,560 |
| Beta | 2.088 |
| Bid | 19.11 |
| Bid Size | 2 |
| Board Risk | 8 |
| Book Value | 0.898 |
| City | Seattle |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 26.44 |
| Current Ratio | 4.795 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 26.87 |
| Day Low | 26.11 |
| Debt To Equity | 272.464 |
| Display Name | Adaptive Biotechnologies |
| Earnings Call Timestamp End | 1,785,357,000 |
| Earnings Call Timestamp Start | 1,785,357,000 |
| Earnings Timestamp | 1,785,355,200 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | -21,327,000 |
| Ebitda Margins | -0.06923 |
| Enterprise To Ebitda | -201.327 |
| Enterprise To Revenue | 13.937 |
| Enterprise Value | 4,293,705,984 |
| Eps Current Year | -0.54108 |
| Eps Forward | -0.18473 |
| Eps Trailing Twelve Months | -0.4 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 206 659 0667 |
| Fifty Day Average | 22.673 |
| Fifty Day Average Change | 3.7670002 |
| Fifty Day Average Change Percent | 0.16614476 |
| Fifty Two Week Change Percent | 100.60699 |
| Fifty Two Week High | 26.87 |
| Fifty Two Week High Change | -0.4300003 |
| Fifty Two Week High Change Percent | -0.016002988 |
| Fifty Two Week Low | 12.0 |
| Fifty Two Week Low Change | 14.440001 |
| Fifty Two Week Low Change Percent | 1.2033334 |
| Fifty Two Week Range | 12.0 - 26.87 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,561,642,200,000 |
| Float Shares | 125,463,079 |
| Forward Eps | -0.18473 |
| Forward P E | -143.12782 |
| Free Cashflow | 18,976,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 624 |
| Fullday Change | 0.280001 |
| Fullday Change Percent | 1.07034 |
| Fullday Price | 26.8 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.46942002 |
| Gross Profits | 144,619,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01306 |
| Held Percent Institutions | 0.99244004 |
| Implied Shares Outstanding | 159,595,842 |
| Industry | Diagnostics & Research |
| Industry Disp | Diagnostics & Research |
| Industry Key | diagnostics-research |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington. |
| Long Name | Adaptive Biotechnologies Corporation |
| Market | us_market |
| Market Cap | 4,219,714,048 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_100147173 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -63,854,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,175,027,226 |
| Number Of Analyst Opinions | 7 |
| Open | 26.23 |
| Operating Cashflow | -21,009,000 |
| Operating Margins | -0.2204 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 206 659 0067 |
| Post Market Change | 0.3599987 |
| Post Market Change Percent | 1.3615685 |
| Post Market Price | 26.8 |
| Post Market Time | 1,787,874,076 |
| Previous Close | 26.16 |
| Price Eps Current Year | -48.865234 |
| Price Hint | 2 |
| Price To Book | 29.443207 |
| Price To Sales Trailing12 Months | 13.696769 |
| Profit Margins | -0.20726 |
| Quick Ratio | 4.51 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | 0.280001 |
| Regular Market Change Percent | 1.07034 |
| Regular Market Day High | 26.87 |
| Regular Market Day Low | 26.11 |
| Regular Market Day Range | 26.11 - 26.87 |
| Regular Market Open | 26.23 |
| Regular Market Previous Close | 26.16 |
| Regular Market Price | 26.44 |
| Regular Market Time | 1,787,860,801 |
| Regular Market Volume | 1,944,008 |
| Return On Assets | -0.04117 |
| Return On Equity | -0.38759 |
| Revenue Growth | 0.215 |
| Revenue Per Share | 1.984 |
| Sand P52 Week Change | 0.1890428 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 159,595,842 |
| Shares Percent Shares Out | 0.083500005 |
| Shares Short | 13,323,767 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 11,396,387 |
| Short Name | Adaptive Biotechnologies Corpor |
| Short Percent Of Float | 0.105500005 |
| Short Ratio | 4.98 |
| Source Interval | 15 |
| State | WA |
| Symbol | ADPT |
| Target High Price | 28.0 |
| Target Low Price | 21.0 |
| Target Mean Price | 25.07143 |
| Target Median Price | 25.0 |
| Total Cash | 344,255,008 |
| Total Cash Per Share | 2.157 |
| Total Debt | 410,499,008 |
| Total Revenue | 308,080,992 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.4 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 17.3708 |
| Two Hundred Day Average Change | 9.0692005 |
| Two Hundred Day Average Change Percent | 0.5220946 |
| Type Disp | Equity |
| Volume | 1,944,008 |
| Website | https://www.adaptivebiotech.com |
| Zip | 98,109 |